Formulary restrictions on brand name noninsulin antihyperglycemic drugs have little impact on treatment intensification patterns among low-income patients with diabetes in Medicare Part D.
Catherine E. Cooke, PharmD
Advertisement
Articles by Catherine E. Cooke, PharmD
This retrospective study found no benefit of a disease management program compared with usual care on utilization of secondary prevention pharmacotherapies in postmyocardial infarction patients.
Advertisement
Latest Updated Articles
- Pharmacotherapy After Myocardial Infarction: Disease Management Versus Usual Care
Published: June 7th 2008 | Updated:
- Impact of Formulary Restrictions on Medication Intensification in Diabetes Treatment
Published: May 7th 2018 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research COuld Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
Value-Based Care Interventions and Management of CKD Progression
4
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
5
